Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals

NCT04510012 is registered in ClinicalTrials.gov with Insel Gruppe AG, University Hospital Bern as lead sponsor.

NCT NCT04510012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04510012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterizing the Immune Response and Neuronal Damage in SARS-CoV-2 Infected Individuals
Lead sponsor
Insel Gruppe AG, University Hospital Bern
Phase
Observational
Overall status
Completed
Start date
March 5, 2020
Completion date
January 30, 2021
Enrollment
88 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov infection